Receptor distribution, retinal architecture, extracellular barriers, and cell-specific entry mechanisms can all change the route a capsid takes through the tissue.
Human retinal explants provide a practical bridge between animal studies and clinical development. They preserve the layered organization of the donor retina—at least for a limited ex vivo window—while allowing researchers to compare capsids directly in human photoreceptors, Müller glia, and inner retinal neurons. For vector selection, that distinction is decisive. A capsid that performs well in a mouse may not reach the human outer nuclear layer with the same efficiency, and a construct that appears modest in a conventional model may prove more useful once tested against human retinal cell surfaces.
The central question is therefore not whether an AAV vector can express a reporter somewhere in the retina. It is whether the vector reaches the intended cell population, penetrates the relevant retinal layer, and does so reproducibly enough to justify the next stage of development.
The translational gap begins with the cell surface
AAV tropism is often discussed as if it were a fixed property of the capsid. In practice, tropism is a relationship between the capsid and the tissue it encounters. The same vector can behave differently across species because the receptors and co-receptors available on the cell surface are not identical.
That difference matters most when the therapeutic target sits behind several layers of retinal tissue. A vector intended for photoreceptors must navigate the physical organization of the retina and reach cells in or near the outer nuclear layer. A vector intended for Müller glia or inner retinal neurons faces a different distribution problem. The route of delivery, the retinal region, the tissue condition, and the promoter used to read out expression all influence the result.
Rodent models remain valuable for assessing safety, dosing logic, surgical delivery, and broad biological activity. Non-human primate studies can add anatomical and translational context. But neither model should be treated as a perfect proxy for human retinal tropism. Species differences in cell-surface receptor profiles create a gap that cannot be closed by assuming that a familiar serotype will behave the same way in human donor tissue.
This is where human retinal explants earn their place. An organotypic explant is not a miniature clinical trial, and it cannot reproduce long-term immune surveillance, circulation, vitreous movement, or the complete surgical environment. It does, however, retain the human retinal architecture needed to ask a more direct question: which cells does this vector actually reach in human tissue?
Animal data can establish a direction. Human explants can show whether the vector is still travelling in that direction when the species changes.
The clinical history of ocular AAV gene therapy demonstrates both the promise and the limits of the platform. The 2017 FDA approval of Luxturna, an AAV2-RPE65 therapy, established clinical proof of concept for retinal gene replacement. It did not turn AAV2 into a universal retinal delivery vehicle. Each new target still requires a fresh assessment of cell access, expression pattern, surgical route, and dose-related risk.
Building an explant model that answers a clinical question
The quality of a retinal explant experiment is determined before the vector is added. Tissue procurement, dissection, regional sampling, and the timing of culture all shape the biological signal that follows.
Human organotypic retinal explants are typically derived from post-mortem donor eyes and placed on transmembrane inserts. The insert format supports the tissue while allowing culture conditions to be controlled around it. Researchers may compare macular, mid-peripheral, and peripheral retinal samples because retinal regions are not interchangeable. Cell composition, layer thickness, degeneration status, and access to the target population can vary across the same donor eye.
A useful design begins with the intended clinical application rather than with the capsid list. If the programme is focused on photoreceptor replacement, the experiment should preserve and evaluate the outer retinal layers. If the target is Müller glia or inner retinal neurons, the readout must distinguish those populations rather than relying on a whole-tissue fluorescence signal.
Several practical decisions determine whether the result will be interpretable:
- Regional sampling: Macular, mid-peripheral, and peripheral explants should be tracked separately rather than pooled into a single human-retina result. A capsid may show regional preferences that disappear in an averaged measurement.
- Tissue orientation: The explant must preserve the retinal surface and layer relationship relevant to the intended route of exposure. A dissection that damages the outer retina can make a photoreceptor-targeting vector appear weaker than it is.
- Culture timing: Human explants are usually evaluated over a short viability window. Studies commonly assess reporter expression after approximately seven to eight days of ex vivo vector incubation.
- Cell-specific readout: GFP or another reporter can show where expression occurs, but the signal needs to be assigned to photoreceptors, Müller cells, or inner retinal neurons through appropriate histological analysis.
- Matched controls: Wild-type or established capsids provide the reference point for engineered variants. Without a consistent control, a new capsid can look impressive simply because the comparator was poorly suited to the tissue.
- Donor metadata: Post-mortem interval, donor age, ocular history, and tissue condition can influence explant performance. These variables do not automatically invalidate a study, but they need to remain visible when results are compared.
The explant is a model of delivery and cell access, not a complete model of therapeutic durability. The available evidence supports a short assessment period, generally around seven days, with some studies extending to eight days. Long-term expression stability beyond the practical viability of the culture remains unresolved. A strong early reporter signal should therefore be read as evidence of transduction under the tested conditions, not as proof of durable clinical expression.
What the tissue can and cannot tell you
| Experimental question | What a human retinal explant can show | What it cannot establish alone |
|---|---|---|
| Does the capsid reach photoreceptors? | Relative cell targeting and reporter expression in the outer retina | Long-term photoreceptor function or durable vision recovery |
| Does the vector penetrate retinal layers? | Distribution of signal across the retinal architecture | Full in vivo biodistribution after clinical administration |
| Does a new capsid outperform a standard control? | Comparative transduction under matched ex vivo conditions | A final human dose or therapeutic index |
| Does regional tissue affect performance? | Differences between macular, mid-peripheral, and peripheral samples | The effect of complete ocular anatomy and surgical flow |
| Is the vector suitable for clinical translation? | Evidence supporting or weakening the next development step | Clinical efficacy, immune response, or graft and tissue integration |
The practical value lies in narrowing uncertainty. An explant experiment can prevent a programme from carrying an unsuitable capsid into more expensive animal, manufacturing, or clinical work. It can also reveal that a vector is highly selective for one retinal population but poorly suited to another.
What standard serotypes do in human retinal tissue
Comparative studies in human retinal explants have shown meaningful differences among commonly used AAV serotypes. AAV2/4 and AAV2/5 demonstrate high efficiency in transducing photoreceptor cells under the tested conditions. AAV2/5 is particularly notable for strong specificity toward the outer nuclear layer, which makes it relevant when the therapeutic strategy depends on reaching photoreceptors rather than broadly distributing expression across the retina.
AAV2/8 presents a useful counterexample. Its performance in human photoreceptors is consistently low in explant models. That finding is clinically relevant because results from other species can create a misleading expectation of broad retinal activity. A vector that is familiar from preclinical work should not receive a presumption of human photoreceptor access.
This does not make AAV2/8 universally unsuitable. It means that its suitability depends on the target cell, delivery route, promoter, and disease context. A low photoreceptor signal may not matter in a programme focused on another retinal population. What matters is that the conclusion is made from the intended human target, not from the serotype’s reputation elsewhere.
A practical comparison looks like this:
| Capsid or serotype | Observed relevance in human retinal explants | Developmental interpretation |
|---|---|---|
| AAV2/4 | High photoreceptor transduction in comparative explant studies | A candidate for programmes requiring outer retinal access |
| AAV2/5 | High photoreceptor transduction with strong outer nuclear layer specificity | Particularly relevant for photoreceptor-directed delivery |
| AAV2/8 | Consistently low photoreceptor transduction in human explants | Should not be selected for human photoreceptor targeting on animal data alone |
| AAV2/2 | Used as a standard comparator in studies of engineered capsids | Useful reference point rather than a universal benchmark for every target |
| AAV-32.33 | Higher photoreceptor and Müller cell transduction than standard AAV2/2 and AAV2/8 controls in reported explant comparisons | A candidate for broader or dual retinal cell access |
| AAV-rh10 | Increased photoreceptor and Müller cell transduction in human and non-human primate explants compared with standard controls | Supports further evaluation where both cell populations are relevant |
| AAV2.7m8, AAV2.NN, AAV2.GL | Selected and validated for improved penetration across retinal cell layers in human explants and retinal organoids | Useful engineered options when layer penetration is the limiting problem |
The table should not be read as a universal ranking. Tropism is not a single score. A capsid may be strong in photoreceptors but weak in Müller glia, or show broad penetration without the expression pattern required for a therapeutic programme. Promoter choice also changes the visible result. The same physical delivery event can produce different reporter patterns depending on the transcriptional cassette.
This is why human retinal tissue transduction efficiency should be reported by cell type and retinal layer wherever possible. A whole-explant fluorescence value may be easy to generate, but it can hide the difference between useful target-cell expression and signal from an unintended population.
Engineered capsids: better penetration is not the same as better therapy
The next generation of AAV candidates is designed to address the limitations of conventional serotypes. Engineered variants such as AAV2.7m8, AAV2.NN, and AAV2.GL have been selected and validated in human retinal explants and retinal organoids for enhanced penetration across retinal cell layers. AAV-32.33 and AAV-rh10 have shown higher transduction efficiency for photoreceptors and Müller cells than standard AAV2/2 and AAV2/8 controls in human and non-human primate retinal explants.
For a translational team, those findings are encouraging but not self-interpreting. Greater penetration can improve access to a target population, yet broader distribution may also complicate specificity, dosing, or safety assessment. The question is not simply whether an engineered capsid enters more cells. The question is whether it reaches the right cells at a level and distribution compatible with the intended therapeutic mechanism.
A capsid review should therefore move through several distinct questions:
1. Which cell population is the therapy trying to modify?
Photoreceptors, Müller glia, and inner retinal neurons require different delivery assumptions. A broad signal is not automatically useful if the therapeutic payload needs restricted expression.
2. Does the capsid cross the retinal layers that stand between the vector and its target?
This is where variants with enhanced layer penetration may have an advantage over wild-type controls. The tissue image matters as much as the aggregate signal.
3. Is the result consistent across retinal regions?
A macular explant may not reproduce the behaviour seen in peripheral retina. Regional differences should be treated as biological information, not experimental noise to be averaged away.
4. Does the reporter readout match the clinical mechanism?
A strong GFP signal confirms expression under the tested conditions. It does not by itself demonstrate therapeutic protein activity, correction of a disease phenotype, or functional recovery.
5. Can the apparent advantage survive a matched comparison?
Capsids should be evaluated at comparable experimental conditions, with the same tissue preparation and an appropriate conventional control. Otherwise, the study measures differences in protocol as much as differences in vector biology.
There is also a manufacturing and clinical reality behind the capsid choice. An engineered vector that performs well in human donor tissue still has to be produced consistently, characterized, delivered through a workable surgical route, and assessed for immune and inflammatory consequences. The explant model does not replace those steps. It helps decide which candidates deserve them.
The best capsid is not the one with the brightest image. It is the one whose distribution fits the target, the payload, the surgical route, and the risk the patient will actually carry.
Making the seven-day readout useful
Most human retinal explant studies work within a narrow observation period. Around seven days is a common point for assessing reporter expression after ex vivo incubation, with some protocols extending to eight days. That short interval is a limitation, but it is also a strength: the experiment can be standardized around an early, comparable endpoint before tissue deterioration overwhelms the biological signal.
The readout should be planned before the first explant is prepared. A robust analysis typically separates at least four dimensions:
- Target-cell identity: Which retinal cells contain the reporter signal?
- Layer distribution: Does expression remain near the exposed surface, or does it reach the outer nuclear layer and other intended compartments?
- Regional consistency: Does the pattern hold in macular, mid-peripheral, and peripheral samples?
- Comparator performance: Is the engineered capsid better than the chosen standard under the same conditions?
Reporter intensity alone is a poor substitute for these measurements. A bright signal concentrated in an unintended cell population may be less valuable than a more moderate signal in the correct target cells. Similarly, widespread expression can indicate successful penetration, but it may not suit a therapy that requires cell-restricted activity.
The assay should also keep transduction separate from tissue quality. A damaged or poorly preserved explant can produce low expression for reasons unrelated to capsid biology. Tissue condition should be documented alongside the vector result, not treated as an afterthought. In practical terms, the laboratory needs to know whether it is observing a weak vector or a weak piece of tissue.
A useful seven-day workflow is built around decision points rather than a single endpoint:
1. Confirm tissue suitability and regional identity.
Record the donor tissue source and whether the sample represents macular, mid-peripheral, or peripheral retina.
2. Preserve layer relationships during preparation.
Photoreceptor studies are especially sensitive to damage involving the outer retina and outer nuclear layer.
3. Apply the vector under matched conditions.
Compare standard and engineered capsids within the same experimental framework so that tissue and culture effects do not distort the result.
4. Assess expression at the established early endpoint.
A seven- to eight-day readout can support comparative transduction analysis while remaining within the practical ex vivo culture window.
5. Map the signal to cell type and layer.
The question is not merely how much reporter is present, but where it is and whether that location supports the therapeutic objective.
6. Carry uncertainty into the next model.
A promising explant result supports further development; it does not establish durability, safety, dosing, or clinical benefit.
The final step is easy to skip. Researchers may treat a strong human-tissue signal as a conclusion when it is more accurately a selection event. The explant narrows the field of vectors and clarifies the biological problem. It does not remove the need for surgical feasibility studies, toxicology, manufacturing comparability, or clinical monitoring.
A more disciplined path from donor retina to trial design
The value of human ocular tissue is greatest when it is used to answer a question that animal models cannot answer cleanly. For AAV ocular gene delivery, that question is often cell access: which capsid can cross the human retinal environment and express in the intended population?
The answer should be framed with the limits of the model in view. Human explants preserve important anatomical and cellular features, but they do not reproduce the full immune environment, intraocular fluid dynamics, surgical pressure, or long-term tissue response. They are also constrained by donor variability and a limited culture lifespan. No single explant result should be promoted into a clinical prediction without those qualifications.
Still, the model can change development decisions in a concrete way. It can show that AAV2/5 is better aligned with a photoreceptor-directed programme than a serotype with low human photoreceptor transduction. It can identify engineered capsids such as AAV-32.33 or AAV-rh10 when the programme requires access to both photoreceptors and Müller cells. It can indicate whether AAV2.7m8, AAV2.NN, or AAV2.GL warrants further study for improved retinal layer penetration. And it can stop a team from assuming that an animal result will transfer without human validation.
The strongest use of the retinal explant model is therefore not to declare a winner. It is to make the next experiment more honest. A capsid enters later development with a clearer understanding of its target cells, its regional behaviour, its penetration limits, and the evidence still missing.
That is the practical standard for translational vector selection. Before a delivery system is asked to carry a therapeutic gene into a patient’s retina, it should first demonstrate that it can find the right human cells in human tissue.